J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jafron Biomedical Co Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Total Liabilities
ÂĄ2.4B
CAGR 3-Years
23%
CAGR 5-Years
48%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Total Liabilities
ÂĄ665.8m
CAGR 3-Years
73%
CAGR 5-Years
64%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Total Liabilities
ÂĄ3.5B
CAGR 3-Years
-5%
CAGR 5-Years
20%
CAGR 10-Years
24%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Total Liabilities
ÂĄ21.8B
CAGR 3-Years
33%
CAGR 5-Years
27%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Total Liabilities
ÂĄ9.4B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
39%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Total Liabilities
ÂĄ6.5B
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
47.02 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Total Liabilities?
Total Liabilities
2.4B CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Total Liabilities amounts to 2.4B CNY.

What is Jafron Biomedical Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
48%

Over the last year, the Total Liabilities growth was 1%. The average annual Total Liabilities growth rates for Jafron Biomedical Co Ltd have been 23% over the past three years , 48% over the past five years .

Back to Top